Aros Pharma ApS has found a new way to treat pain associated with irritable bowel syndrome. The company is developing an ASIC1A antagonist that specifically reduces gastrointestinal pain and could be an effective adjunct therapy to available irritable bowel syndrome treatments.

While there are many pain therapeutics on the market, common side effects make them generally unsuitable to treat gastrointestinal pain.